European stakeholder learnings regarding biosimilars: Part I – improving biosimilar understanding and adoption

BioDrugs

Liese Barbier[1*], Steven Simoens[1], Arnold G. Vulto[1,2+*], Isabelle Huys[1+]

[1]KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
[2]Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands

[+] Joint last author: these authors contributed equally to this work

[*] Corresponding author:

Arnold G. Vulto Contact: a.vulto@gmail.com

Liese Barbier Contact: liese.barbier@kuleuven.be

Online Resource 6 Participant's characteristics – II

Participants' characteristics		
Characteristics	**Participants (n=44)**	
	n	%
Country		
Austria	1	2
Belgium	5	11
Croatia	1	2
Denmark	3	7
EU perspective*	16	36
France	1	2
Ireland	1	2
Italy	1	2
Malta	1	2
Poland	1	2
Portugal	1	2
The Netherlands	7	16
UK	1	2
Spain	3	7
Switzerland	1	2
Stakeholder group		
Hospital pharmacist	10	23
Nurse	9	20
Patient (representative)	9	20
Physician	9	20
Regulator	7	16
Therapeutic area		
Endocrinology	1	2
Gastro-enterology	8	18
Hemato-oncology	7	16
Nephrology	1	2
Non-disease specific	21	48
Rheumatology	6	14
EU: European, n: number		
**Representing participants from European organizations or institutions (e.g. representatives of European stakeholder associations). Regulators involved in biosimilar regulatory activities on a European level (i.e. members of a European Medicines Agency committee and/or working party, such as the Biosimilar Medicinal Products Working Party), are included in this category*		
Participants with a pan-European perspective often also provided (home) country specific insights and/or examples in addition to their pan-European perspective		